Sector News

Celladon halves its workforce to conserve cash after gene therapy meltdown

May 15, 2015
Life sciences
Reeling after the Phase IIb failure of its “breakthrough” gene therapy for heart failure, Celladon ($CLDN) is slashing its budget and payroll, vowing to find a way forward that preserves value for its investors.
 
Last month, the company disclosed that its top prospect, Mydicar, failed to reduce hospitalizations, improve cardio survival rates or free patients from the need for ventricular-assist devices and heart transplants, an across-the-board failure that decimated the company’s market value.
 
Now the San Diego biotech is scrimping to stay alive, reducing its 34-person staff by 50% this quarter in an effort to save cash. Celladon is also backing out of a pair of manufacturing agreements with Novasep and Lonza–no longer needed now that Mydicar isn’t headed for Phase III–and the company is walking away from a loan agreement under which it would have taken on $15 million in debt.
 
Celladon closed the quarter with $70.6 million in cash and equivalents, enough to keep the doors open as management evaluates its pipeline and looks into “strategic alternatives to maximize value for our stockholders,” the company said in a regulatory filing. The company has already nixed an ongoing Phase I trial testing Mydicar in conjunction with a heart device and is now weighing what to do with a preclinical stem cell program to treat heart attack and an early-stage small-molecule drug with the same target as Mydicar.
 
“We are in the process of conducting an extensive review of the (Mydicar) data in the attempt to better understand the observed negative outcome,” CEO Krisztina Zsebo said in a statement. “Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value.”
 
To Celladon’s credit, throughout the Mydicar debacle, management has been up front with the public, bucking a trend in biotech and declining to mine for positive results in its failed trial or spin the setback as a success.
 
By Damian Garde
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]